Two ways to one goal: new strategy of antiviral therapy for chronic hepatitis C
Abstract
The aim of review. To analyze data of the clinical studies on chronic hepatitis C (CHC) treatment with application of new modes of combined therapy, including selective inhibitor of viral protease.
Key points. New algorithms of antiviral therapy for patients infected by the 1-st virus genotype not treated earlier, and after treatment failure, implicate presence or absence of so-called «induction phase», the kernel of which is application of pegilated interferon-α and ribavirin combination at the beginning of treatment with subsequent addition of the third agent (the direct action antiviral agent). Triple therapy with induction phase strategy is recommended at application of boceprevir as the third agent. Another antiviral drug with direct action – telaprevir is recommended for prescription from first day of treatment.
Conclusion. Taking into account an apparent positive effect of induction phase for boceprevir modes of treatment and absence of that evidence for telaprevir application, both new antiviral strategies are justified for clinical application in CHC patients.
About the Author
S. N. Batskikh
Federal Budget Institution of Science «Central Research Institute of Epidemiology» of the Federal Service on Customers' Rights Protection and Human Well-being Surveillance
Russian Federation
Russian Federation
References
1. Bacon B.R., Gordon S.C., Lawitz E. et al. Boceprevir for previously treated chronic HCV genotype 1 infection // N. Engl. J. Med. – 2011. – Vol. 364, N 13. – P. 1207–1217.
2. Boceprevir [package insert]. – 2012. [Available from: http://www.merck.com/product/usa/pi_circulars/v/ victrelis/victrelis_pi.pdf]
3. De M.S., Dierynck I., Ghys A. et al. Characterization of HCV variants in non-SVR patients in the REALIZE study suggests that telaprevir exhibits a consistent resistance profile irrespective of a lead-in // J. Hepatol. – 2011. – Vol. 54 (suppl. 1). – P. 475. – A1202.
4. Ferenci P., Laferl H., Scherzer T.M. et al. Peginterferon alfa-2a and ribavirin for 24 weeks in hepatitis C type 1 and 4 patients with rapid virological response // Gastroenterology. – 2008. – Vol. 135, N 2. – P. 451–458.
5. Foster G.R., Zeuzem S., Andreone P. et al. Subanalyses of the telaprevir lead-in arm in the REALIZE study: response at week 4 is not a substitute for prior null response categorization // J. Hepatol. – 2011. – Vol. 54 (suppl. 1). – P. 3–4. – A6.
6. Ghany M.G., Nelson D.R., Strader D.B. et al. An Update on Treatment of Genotype 1 Chronic Hepatitis C Virus Infection: 2011 Practice Guideline by the American Association for the Study of Liver Diseases // Hepatology. – 2011. – Vol. 54, N 4. – P. 1433–1444.
7. Jacobson I.M., McHutchison J.G., Dusheiko G. et al. Telaprevir for previously untreated chronic hepatitis C virus infection // N. Engl. J. Med. – 2011. – Vol. 364, N 25. – P. 2405–2416.
8. Kwo P.Y., Lawitz E.J., McCone J. et al. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial // Lancet. – 2010. – Vol. 376. – P. 705–716.
9. Mangia A., Minerva N., Bacca D. et al. Individualized treatment duration for hepatitis C genotype 1 patients: A randomized controlled trial // Hepatology. – 2008. – Vol. 47, N 1. – P. 43–50.
10. Mauss S., Berg T., Rockstroh J. et al. Short guide to hepatitis C. – Flying Publisher, 2012. – 151 p. [Available from:http://www.flyingpublisher.com/0011.php].
11. Poordad F., McHutchison J.G., Shiffman M.L. et al. Early virological response profiles with telaprevir in combination with peginterferon alfa-2a and ribavirin in genotype 1 HCV treatment-naïve and treatmentexperienced patients are similar // J. Hepatol. – 2010. – Vol. 52 (suppl. 1). – P. 121–122. – A290.
12. Ramachandran P., Fraser A., Agarwal K. et al. UK consensus guidelines for the use of the protease inhibitors boceprevir and telaprevir in genotype 1 chronic hepatitis C infected patients // Aliment. Pharmacol. Ther. – 2012. – Vol. 35, N 6. – P. 647–662.
13. Sullivan J.C., de Meyer S., Bartels D.J. et al. Evolution of treatment-emergent resistant variants in telaprevir phase 3 clinical trials // J. Hepatol. – 2011. – Vol. 54 (suppl. 1). – P. 4–8.
14. Telaprevir [package insert]. – 2012. [Available from: http://pi.vrtx.com/files/uspi_telaprevir.pdf]
15. Yu M.L., Dai C.Y., Huang J.F. et al. Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: a randomized trial // Hepatology. – 2008. – Vol. 47, N 6. – P. 1884–1893.
16. Zeuzem S., Andreone P., Pol S. et al. Telaprevir for retreatment of HCV infection // N. Engl. J. Med. – 2011. – Vol. 364, N 25. – P. 2417–2428.
17. Zeuzem S., Barnard R.J., Howe J.A. et al. Boceprevir resistance-associated variants (RAVS) are observed more frequently in HCV (GT1)-infected patients with poor response to peginterferon alfa-2b/ribavirin // J. Hepatol. – 2011. – Vol. 54 (suppl. 1). – P. 4–5. – A9.
18. Zeuzem S., Buti M., Ferenci P. et al. Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia // J. Hepatol. – 2006. – Vol. 44, N 1. – P. 97–103.
Review
For citations:
Batskikh S.N. Two ways to one goal: new strategy of antiviral therapy for chronic hepatitis C. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2012;22(6):22-26. (In Russ.)
Views:
96
Email this article 
